首页> 美国卫生研究院文献>Journal of Virology >Quantitation of HLA Class II Protein Incorporated into Human Immunodeficiency Type 1 Virions Purified by Anti-CD45 Immunoaffinity Depletion of Microvesicles
【2h】

Quantitation of HLA Class II Protein Incorporated into Human Immunodeficiency Type 1 Virions Purified by Anti-CD45 Immunoaffinity Depletion of Microvesicles

机译:HLA II类蛋白质的定量结合到人类免疫缺陷型1型病毒颗粒中通过微泡抗CD45免疫亲和力纯化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Among the many host cell-derived proteins found in human immunodeficiency virus type 1 (HIV-1), HLA class II (HLA-II) appears to be selectively incorporated onto virions and may contribute to mechanisms of indirect imunopathogenesis in HIV infection and AIDS. However, the amount of HLA-II on the surface of HIV-1 particles has not been reliably determined due to contamination of virus preparations by microvesicles containing host cell proteins, including HLA-II. Even rigorous sucrose density centrifugation is unable to completely separate HIV-1 from microvesicles. CD45, a leukocyte integral membrane protein, is found on microvesicles, yet appears to be excluded from HIV-1 particles. Exploiting this observation, we have developed a CD45-based immunoaffinity depletion method for removing CD45-containing microvesicles that yields highly purified preparations of virions. Examination of CD45-depleted HIV-1MN by high-pressure liquid chromatography, protein sequencing, and amino acid analyses determined a molar ratio of HLA-II to Gag of 0.04 to 0.05 in the purified virions, corresponding to an estimated average of 50 to 63 native HLA-II complexes (i.e., a dimer of α and β heterodimers) per virion. These values are approximately 5- to 10-fold lower than those previously determined for other virion preparations that contained microvesicles. Our observations demonstrate the utility of CD45 immunoaffinity-based approaches for producing highly purified retrovirus preparations for applications that would benefit from the use of virus that is essentially free of microvesicles.
机译:在人类免疫缺陷病毒1型(HIV-1)中发现的许多宿主细胞衍生蛋白中,HLA II类(HLA-II)似乎被选择性地掺入到病毒体中,并可能有助于HIV感染和AIDS的间接免疫发病机制。然而,由于病毒制剂被包含宿主细胞蛋白的微泡(包括HLA-II)污染,因此尚未可靠地确定HIV-1颗粒表面上HLA-II的量。即使严格的蔗糖密度离心也无法将HIV-1与微泡完全分离。 CD45是一种白细胞整合膜蛋白,存在于微泡中,但似乎未从HIV-1颗粒中排除。利用这一观察结果,我们开发了一种基于CD45的免疫亲和力耗竭方法,用于去除含有CD45的微囊泡,从而产生高度纯化的病毒体制剂。通过高压液相色谱,蛋白质测序和氨基酸分析检查CD45耗尽的HIV-1MN,确定纯化病毒体中HLA-II与Gag的摩尔比为0.04至0.05,相当于估计的平均50至63每个病毒体的天然HLA-II复合物(即α和β异二聚体的二聚体)。这些值比先前对于含有微囊泡的其他病毒体制剂所确定的值低约5至10倍。我们的观察结果表明,基于CD45免疫亲和力的方法可用于生产高度纯化的逆转录病毒制剂,从而可受益于使用基本不含微泡的病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号